Suchergebnisse - "Large, Samuel"

PubPharm (11)

1

The Hidden Economic Consequences of Migraine to the UK Government : Burden-of-Disease Analysis Using a Fiscal Framework

enthalten in: Journal of health economics and outcomes research | 2023

von Martins, R. | Large, S. | Russell, R. | +2

2

Estimating the health benefits of timely diagnosis and treatment of transthyretin amyloid cardiomyopathy

enthalten in: Journal of comparative effectiveness research | 2021

von Rozenbaum, M. | Large, S. | Bhambri, R. | +6

3

Impact of Delayed Diagnosis and Misdiagnosis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) : A Targeted Literature Review

enthalten in: Cardiology and therapy | 2021

von Rozenbaum, M. | Large, S. | Bhambri, R. | +6

4

Impact of Delayed Diagnosis and Misdiagnosis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM): A Targeted Literature Review

enthalten in: Cardiology and therapy | 2021

von Rozenbaum, M. | Large, S. | Bhambri, R. | +6

5

Impact of Delayed Diagnosis and Misdiagnosis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM): A Targeted Literature Review

enthalten in: Cardiology and therapy | 2021

von Rozenbaum, M. | Large, S. | Bhambri, R. | +6

6

Impact of Delayed Diagnosis and Misdiagnosis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM): A Targeted Literature Review

enthalten in: Cardiology and therapy | 2021

von Rozenbaum, M. | Large, S. | Bhambri, R. | +6

7

Comparing the Fiscal Consequences of Controlled and Uncontrolled Osteoarthritis Pain Applying a UK Public Economic Perspective

enthalten in: Journal of health economics and outcomes research | 2021

von Martins, R. | Kotsopoulos, N. | Kosaner Kließ, M. | +5

8

Cost-Effectiveness Analysis of Fulvestrant 500 mg in Endocrine Therapy-Naïve Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer in the UK

enthalten in: PharmacoEconomics - open | 2019

von Telford, C. | Bertranou, E. | Large, S. | +3

9

Cost-Effectiveness Analysis of Fulvestrant 500 mg in Endocrine Therapy-Naïve Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer in the UK

enthalten in: PharmacoEconomics - open | 2019

von Telford, C. | Bertranou, E. | Large, S. | +3

10

Cost-effectiveness of pembrolizumab versus brentuximab vedotin for patients with relapsed or refractory classical Hodgkin's lymphoma : a United States payer perspective

enthalten in: Journal of medical economics | 2018

von Large, S. | Hettle, R. | Balakumaran, A. | +2